Outpatient Cilta-cel Shows Promise in Multiple Myeloma, With Early Signs of Lower Costs and Comparable Outcomes

A systematic literature review suggests that outpatient administration of ciltacabtagene autoleucel, or cilta-cel, may be a feasible option for selected patients with relapsed or refractory multiple myeloma, potentially reducing hospital burden and costs without clear evidence of worse outcomes. 

The review synthesized 74 records across 56 unique studies and found that only 90 patients had received cilta-cel in the outpatient setting, underscoring how early the evidence base remains. Even so, the available data point to a model of care that could matter to payers and providers as CAR-T use expands into earlier lines of therapy. 

Cilta-cel is typically given as inpatient treatment because of the risk of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. But the therapy’s toxicities often occur several days after infusion, creating an opening for outpatient delivery with close monitoring and rapid access to hospital admission when needed.

The authors concluded that “OP cilta-cel appears feasible for selected patients and may reduce costs without compromising outcomes.”

Across the limited outpatient evidence, response rates were high. One outpatient study reported an overall response rate of 95%, with complete response and partial response rates of 53% and 43%, respectively. Another outpatient analysis reported 1-year progression-free survival of 86% and 1-year overall survival of 96%. In comparison, inpatient studies showed a median overall response rate of 91%, median 1-year progression-free survival of 76%, and median 1-year overall survival of 85%.

Those comparisons, however, were descriptive rather than definitive. The review emphasized that outpatient and inpatient findings were not adjusted for differences in patient selection, institutional practices, or follow-up. 

Safety findings were also broadly aligned across settings. In outpatient cohorts, any-grade cytokine release syndrome occurred in 79% to 84% of patients, while immune effector cell-associated neurotoxicity syndrome occurred in 17% to 22%. Most events were low grade. In inpatient studies, the median incidence of neurotoxicity was 17%, with reported ranges from 5% to 23%.

Hospitalization after outpatient infusion remained common. Between 86% and 93% of outpatients were later admitted, usually for cytokine release syndrome monitoring or management. Still, the duration of hospitalization was shorter than what was reported in 1 inpatient cohort. Median length of stays ranged from 4 to 6.5 days for outpatients, compared with 19 days for inpatients in 1 study. That difference could be meaningful for hospital capacity, utilization management, and total cost of care.

Economic data were limited but directionally favorable for outpatient administration. One modeling-based analysis estimated savings of about $19 000 per patient treated in the outpatient setting. Other scenario analyses suggested additional savings in cost per complete responder and cost per progression-free survival month when a portion of cilta-cel use shifted outpatient.

For payers and managed care decision-makers, the review raises several practical questions for coverage policy. Outpatient cilta-cel may be most appropriate when centers can demonstrate defined patient selection criteria, caregiver support, daily early monitoring, and fast inpatient escalation pathways. Coverage frameworks may need to distinguish between infusion setting and downstream hospitalization, since outpatient treatment does not eliminate admission risk but may reduce overall resource use. The findings also suggest that site-of-care policies should be tied to operational readiness rather than infusion location alone.

The biggest evidence gap is quality of life. No outpatient-specific quality-of-life data were identified, despite the assumption that avoiding prolonged hospitalization could improve patient experience and functional independence.

For now, the review stops short of establishing outpatient cilta-cel as equivalent to inpatient delivery. But for payers facing growing CAR-T demand, it offers an early signal that outpatient administration could become an important lever for access, capacity, and cost management if prospective multicenter studies confirm the trend.

Key Takeaways:

• Patient selection is critical: Outpatient cilta-cel is viable for carefully selected patients with strong support systems. Coverage should include clear eligibility and site requirements. 
• Efficacy appears similar but remains unproven: Efficacy and safety appear similar to inpatient care, though based on limited, non-comparative data. Payers should treat these findings as preliminary. 
• Requires robust monitoring infrastructure: Delayed toxicities make outpatient care possible, but only with structured monitoring and rapid hospital access. Coverage should be tied to operational readiness. 
• Hospital burden is reduced: Most patients still require hospitalization, but for shorter durations. Policies should consider total care episodes rather than infusion setting alone. 
• Cost savings are meaningful: Outpatient administration may reduce costs by around $19 000 per patient. This supports site-of-care strategies aimed at improving efficiency and access.

Reference

Gregory T, et al. Outpatient versus inpatient administration of ciltacabtagene autoleucel in multiple myeloma: A systematic review of clinical, economic, and humanistic outcomes. Cancers. 2026;18(5):755. doi:10.3390/cancers18050755.